Author

R. R. Bernards

Primary ORCID profile (0000-0001-8677-3423 · 1 paper)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

R. R. BernardsiD1 paper · The Netherlands Cancer Institute

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

A. F. M. Altelaar· 1 shared A. J. R. Heck· 1 shared A. Prahallad· 1 shared A. Ressa· 1 shared B. Evers· 1 shared C. Veldman· 1 shared C. Wang· 1 shared D. Gao· 1 shared

Activity by Year

2017-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 18 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. F. M. Altelaar

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologybioRxivPreprintJul 4, 2023

Somatic mutation of Afadin leads to anchorage independent survival and metastatic growth of breast cancer through alpha E-catenin dependent destabilization of the adherens junction

M. A. Ratze, L. N. Enserink, N. Ishiyama…·P. W. Derksen

This study identifies a somatic Afadin mutation that destabilizes adherens junctions and promotes metastatic growth in breast cancer by disrupting E-catenin binding.

DOI 10.1101/2023.07.04.547654

humanwhole-genome sequencing

𝕏 PostBluesky

Cancer BiologybioRxivJan 23, 2018

phospho-ERK is a response biomarker to a combination of sorafenib and MEK inhibition in liver cancer

R. R. Bernards, C. Wang, H. Jin…·W.-X. Qin

This study identifies phospho-ERK as a biomarker for response to sorafenib and MEK inhibition in liver cancer, showing synergistic effects in tumors with high phospho-ERK levels.

DOI 10.1016/j.jhep.2018.07.004

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivSep 27, 2017

A system-wide approach to monitor responses to synergistic BRAF and EGFR inhibition in colorectal cancer cells

A. Ressa, E. Bosdriesz, J. de Ligt…·A. J. R. Heck

The paper investigates molecular responses to BRAF and EGFR inhibition in colorectal cancer cells, revealing metabolic shifts and MAPK pathway reactivation.

DOI 10.1074/mcp.ra117.000486

humanbulk RNA-seq

𝕏 PostBluesky